EG 427

EG 427's innovative non-replicative HSV-1 vector technology enables delivery of two transgenes with independent expression kinetics in a single vector, offering significant advantages over current gene therapy approaches.

A phase 1b/2a clinical trial has begun testing EG110A, a modified herpes virus vector that delivers botulinum toxin genes to treat neurogenic bladder in spinal cord injury patients.

French biotech EG 427 has raised €27M in Series B funding led by Andera Partners and Bpifrance to advance its lead candidate EG110A into Phase Ib/IIa trials for neurogenic detrusor overactivity.